glp 1 and autoimmune disease Microdosing GLP-1 for conditions: what the research actually shows Glucagon-like peptide-1 receptor agonists in

Malaysia in particular is at risk

recently published a study on 2562 case subjects that showed an increased risk of all thyroid cancers (adjusted HR 1.58, 95% CI 1.271.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.043.5) after 13 years of GLP-1 RA use [78]

[DOI] [PMC free article] [PubMed] [Google Scholar] 292.Keenan S.J., Cooke M.B., Hassan E.B., Chen W.S., Sullivan J., Wu S.X., El-Ansary D., Imani M., Belski R

There's a diabetes tie-in, of course, but if you just want to know about the episode feel free to scroll down

This approval broadened the potential patient population and began generating significant media attention, though mainstream awareness remained modest

3.4 Appetite regulation and weight management Similar to animal studies with deletion of the GIPR gene that exhibit protection toward obesity (53), early genome-wide association studies (GWAS) in humans have revealed the GIPR gene to be associated with BMI (103)